Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CCR4-NOT transcription complex subunit 2 (CNOT2) is a core protein component of the highly conserved eukaryotic CCR4-NOT multiprotein complex, which regulates gene expression at both transcriptional and post-transcriptional levels. CNOT2 lacks catalytic activity but is essential for the structural integrity and deadenylase activity of the complex, governing mRNA degradation, stability, and processing, and mediating transcriptional repression through recruitment of repressor complexes like SMRT/NCoR-HDAC3. It influences cell cycle progression, apoptosis (especially when depleted), maintenance of embryonic stem cell identity, and has been implicated in tumor progression and metastatic susceptibility, particularly in cancer biology. CNOT2 is not currently recognized as a direct therapeutic drug target but is of interest in mechanistic and disease research due to its central regulatory functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CCR4-NOT transcription complex subunit 2 (CNOT2).